Modalis Therapeutics Corporation (TYO:4883)
Japan
· Delayed Price · Currency is JPY 78.00
0.00 (0.00%)
Apr 24, 2025, 3:30 PM JST
Modalis Therapeutics Income Statement
Financials in millions JPY. Fiscal year is January - December.
Millions JPY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2018 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2018 - 2019 |
| Revenue | - | - | 40 | 1 | 342 | Upgrade
|
| Revenue Growth (YoY) | - | - | 3900.00% | -99.71% | -46.89% | Upgrade
|
| Gross Profit | - | - | 40 | 1 | 342 | Upgrade
|
| Selling, General & Admin | 220 | 248 | 213 | 196 | 174 | Upgrade
|
| Research & Development | 1,092 | 2,102 | 1,861 | 1,009 | 531 | Upgrade
|
| Other Operating Expenses | 25 | 20 | 29 | 35 | 35 | Upgrade
|
| Operating Expenses | 1,337 | 2,370 | 2,103 | 1,240 | 740 | Upgrade
|
| Operating Income | -1,337 | -2,370 | -2,063 | -1,239 | -398 | Upgrade
|
| Interest Expense | -8 | -15 | -4 | -1 | - | Upgrade
|
| Currency Exchange Gain (Loss) | 64 | 39 | 76 | 12 | -4 | Upgrade
|
| Other Non Operating Income (Expenses) | -23 | -6 | -4 | 1 | -38 | Upgrade
|
| EBT Excluding Unusual Items | -1,304 | -2,352 | -1,995 | -1,227 | -440 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | - | -2 | - | Upgrade
|
| Asset Writedown | - | -38 | -996 | - | - | Upgrade
|
| Other Unusual Items | -13 | - | 285 | 485 | - | Upgrade
|
| Pretax Income | -1,317 | -2,390 | -2,706 | -744 | -440 | Upgrade
|
| Income Tax Expense | - | 1 | -4 | -6 | 8 | Upgrade
|
| Net Income | -1,317 | -2,391 | -2,702 | -738 | -448 | Upgrade
|
| Net Income to Common | -1,317 | -2,391 | -2,702 | -738 | -448 | Upgrade
|
| Shares Outstanding (Basic) | 46 | 31 | 29 | 29 | 26 | Upgrade
|
| Shares Outstanding (Diluted) | 46 | 31 | 29 | 29 | 26 | Upgrade
|
| Shares Change (YoY) | 48.96% | 6.39% | 1.23% | 9.12% | 11.78% | Upgrade
|
| EPS (Basic) | -28.55 | -77.21 | -92.83 | -25.67 | -17.00 | Upgrade
|
| EPS (Diluted) | -28.55 | -77.21 | -92.83 | -25.67 | -17.00 | Upgrade
|
| Free Cash Flow | -1,432 | -2,293 | -2,092 | -854 | -392 | Upgrade
|
| Free Cash Flow Per Share | -31.05 | -74.05 | -71.87 | -29.70 | -14.88 | Upgrade
|
| Gross Margin | - | - | 100.00% | 100.00% | 100.00% | Upgrade
|
| Operating Margin | - | - | -5157.50% | -123900.00% | -116.37% | Upgrade
|
| Profit Margin | - | - | -6755.00% | -73800.00% | -130.99% | Upgrade
|
| Free Cash Flow Margin | - | - | -5230.00% | -85400.00% | -114.62% | Upgrade
|
| EBITDA | -1,336 | -2,369 | -1,940 | -1,162 | -341 | Upgrade
|
| EBITDA Margin | - | - | - | - | -99.71% | Upgrade
|
| D&A For EBITDA | 0.73 | 0.73 | 123 | 77 | 57 | Upgrade
|
| EBIT | -1,337 | -2,370 | -2,063 | -1,239 | -398 | Upgrade
|
| EBIT Margin | - | - | - | - | -116.37% | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.